NCT01540500View on ClinicalTrials.gov

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Healthy Volunteers
Interventions
DRUG

Tasimelteon

5.66 mg dose on Day 1 and Day 8

DRUG

Fluvoxamine

50 mg Dose on Days 2-8

Trial Locations (1)

65802

Bio-Kinetic Clinical Applications, Springfield

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY